Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review

References

• Gestational hypertension and preeclampsia: ACOG practice bulletin summary, number 222. Obstet Gynecol. 2020;135(6):149–11. doi: 10.1097/AOG.0000000000003892
   PubMed Web of Science ®Google Scholar
• Chappell LC, Cluver CA, Kingdom J, et al. Pre-eclampsia. Lancet. 2021;398(10297):341–54. doi: 10.1016/S0140-6736(20)32335-7
   PubMed Web of Science ®Google Scholar
• Poon LC, Shennan A, Hyett JA, et al. The international federation of gynecology and obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019; 145 (Suppl 1):1–33.10.1002/ijgo.12802
   PubMed Web of Science ®Google Scholar
• Roberts JM, Rich-Edwards JW, McElrath TF, et al. Subtypes of preeclampsia: recognition and determining clinical usefulness. Hypertension. 2021;77(5):1430–41. doi: 10.1161/HYPERTENSIONAHA.120.14781
   PubMed Web of Science ®Google Scholar
• Obed S, Patience A. Birth weight and ponderal index in pre-eclampsia: a comparative study. Ghana Med J. 2006;40(1):8–13.
   PubMedGoogle Scholar
• Chandra I, Sun L. Preterm and term preeclampsia: differences in biochemical parameter and pregnancy outcomes. Postgrad Med. 2018;130(8):703–7. doi: 10.1080/00325481.2018.1527169
   PubMed Web of Science ®Google Scholar
• Ives CW, Sinkey R, Rajapreyar I, et al. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 76(14):1690–1702. 10.1016/j.jacc.2020.08.014
   PubMed Web of Science ®Google Scholar
• Ananth CV, Duzyj CM, Yadava S, et al. Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010. Hypertension. 2019;74(5):1089–95. doi: 10.1161/HYPERTENSIONAHA.119.12968
   PubMed Web of Science ®Google Scholar
• Loussert L, Vidal F, Parant O, et al. Aspirin for prevention of preeclampsia and fetal growth restriction. Prenat Diagn. 2020;40(5):519–27. doi: 10.1002/pd.5645
   PubMed Web of Science ®Google Scholar
• Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019;366:15119. doi: 10.1136/bmj.l5119
   Google Scholar
• Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014; 36(5):416–441. 10.1016/S1701-2163(15)30588-0
   PubMedGoogle Scholar
• Lowe SA, Bowyer L, Lust K, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55(5):e1–29. doi: 10.1111/ajo.12399
   PubMed Web of Science ®Google Scholar
• Butalia S, Audibert F, Côté AM, et al. Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy. Can J Cardiol. 2018;34(5):526–31. doi: 10.1016/j.cjca.2018.02.021
   PubMed Web of Science ®Google Scholar
• WHO Guidelines Approved by the Guidelines Review Committee. WHO recommendations: policy of interventionist versus expectant management of severe pre-eclampsia before term. Geneva: World Health Organization © World Health Organization 2018; 2018.
   Google Scholar
• Gu W, Lin J, Hou YY, et al. Effects of low-dose aspirin on the prevention of preeclampsia and pregnancy outcomes: a randomized controlled trial from Shanghai, China. Eur J Obstet Gynecol Reprod Biol. 2020;248:156–63. doi: 10.1016/j.ejogrb.2020.03.038
   PubMed Web of Science ®Google Scholar
• Mirabito Colafella KM, Neuman RI, Visser W, et al. Aspirin for the prevention and treatment of pre-eclampsia: a matter of COX-1 and/or COX-2 inhibition? Basic Clin Pharmacol Toxicol. 2020;127(2):132–41. doi: 10.1111/bcpt.13308
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–22. doi: 10.1056/NEJMoa1704559
   PubMed Web of Science ®Google Scholar
• Lan PG, Gillin AG, Pelosi M, et al. Effect of early use of low-dose aspirin therapy on late-onset preeclampsia. J Matern Fetal Neonatal Med. 2019;32(13):2137–42. doi: 10.1080/14767058.2018.1427718
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Nicolaides KH, Poon LC Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2022; 226(2s):S1108–s19. 10.1016/j.ajog.2020.08.045
   PubMed Web of Science ®Google Scholar
• Van Doorn R, Mukhtarova N, Flyke IP, et al. Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: a systematic review and meta-analysis. PLoS One. 2021;16(3):e0247782. doi: 10.1371/journal.pone.0247782
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):492–5. doi: 10.1002/uog.18816
   PubMed Web of Science ®Google Scholar
• Odigboegwu O, Pan LJ, Chatterjee P. Use of antihypertensive drugs during preeclampsia. Front Cardiovasc Med. 2018;5:50. doi: 10.3389/fcvm.2018.00050
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84. doi: 10.7326/M14-2385
   PubMed Web of Science ®Google Scholar
• Savović J, Weeks L, Sterne JA, et al. Evaluation of the Cochrane Collaboration’s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014;3(1):37. doi: 10.1186/2046-4053-3-37
   PubMedGoogle Scholar
• Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349(sep24 5):g5630. doi: 10.1136/bmj.g5630
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–17. doi: 10.1177/0272989X12458724
   PubMed Web of Science ®Google Scholar
• Yu-Kang T. Node-splitting generalized linear mixed models for evaluation of inconsistency in network meta-analysis. Value Health. 2016;19(8):957–63. doi: 10.1016/j.jval.2016.07.005
   PubMed Web of Science ®Google Scholar
• Bijvank SW, Visser W, Duvekot JJ, et al. Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;189:106–111. doi: 10.1016/j.ejogrb.2015.02.002
   PubMed Web of Science ®Google Scholar
• Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019;394(10203):1011–21. doi: 10.1016/S0140-6736(19)31282-6
   PubMed Web of Science ®Google Scholar
• Moodley J, Gouws E. A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. Br J Obstet Gynaecol. 1992;99(9):727–30. doi: 10.1111/j.1471-0528.1992.tb13872.x
   PubMedGoogle Scholar
• Montan S, Anandakumar C, Arulkumaran S, et al. Randomised controlled trial of methyldopa and isradipine in preeclampsia–effects on uteroplacental and fetal hemodynamics. J Perinat Med. 1996;24(2):177–84. doi: 10.1515/jpme.1996.24.2.177
   PubMed Web of Science ®Google Scholar
• Bolte AC, van Eyck J, Kanhai HH, et al. Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome. Am J Obstet Gynecol. 1999; 180(2 Pt 1):371–377. 10.1016/S0002-9378(99)70216-4
   PubMed Web of Science ®Google Scholar
• Elatrous S, Nouira S, Ouanes Besbes L, et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. Intensive care Med. 2002;28(9):1281–6. doi: 10.1007/s00134-002-1406-3
   PubMed Web of Science ®Google Scholar
• Hanff LM, Vulto AG, Bartels PA, et al. Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients. J Hypertens. 2005;23(12):2319–26. doi: 10.1097/01.hjh.0000188729.73807.16
   PubMed Web of Science ®Google Scholar
• Arias-Hernández G, Vargas-De-León C, Calzada-Mendoza CC, et al. Efficacy of diltiazem for the control of blood pressure in puerperal patients with severe preeclampsia: a randomized, single-blind, controlled trial. Int J Hypertens. 2020;2020:5347918. doi: 10.1155/2020/5347918
   PubMed Web of Science ®Google Scholar
• Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther. 2000;292(2):606–9.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Feldman RL, Whittle J, et al. Effect of diltiazem in patients with variant angina: a randomized double-blind trial. Am Heart J. 1981;101(6):719–25. doi: 10.1016/0002-8703(81)90606-2
   PubMed Web of Science ®Google Scholar
• Balasubramaniam R, Chawla S, Mackenzie L, et al. Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts. Pflugers Arch - Eur J Physiol. 2004;449(2):150–8. doi: 10.1007/s00424-004-1321-2
   PubMed Web of Science ®Google Scholar
• Klinke WP, Kvill L, Dempsey EE, et al. A randomized double-blind comparison of diltiazem and nifedipine in stable angina. J Am Coll Cardiol. 1988;12(6):1562–7. doi: 10.1016/S0735-1097(88)80026-3
   PubMed Web of Science ®Google Scholar
• Glasser SP, Gana TJ, Pascual LG, et al. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. Am Heart J. 2005;149(2):e1–9. doi: 10.1016/j.ahj.2004.08.002
   PubMed Web of Science ®Google Scholar
• Ringholm L, Damm JA, Vestgaard M, et al. Diabetic nephropathy in women with preexisting diabetes: from pregnancy planning to breastfeeding. Curr Diab Rep. 2016;16(2):12. doi: 10.1007/s11892-015-0705-3
   PubMed Web of Science ®Google Scholar
• Peacock WF, Hilleman DE, Levy PD, et al. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012; 30(6):981–993. 10.1016/j.ajem.2011.06.040
   PubMed Web of Science ®Google Scholar
• Molvi SN, Mir S, Rana VS, et al. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet. 2012;285(6):1553–62. doi: 10.1007/s00404-011-2205-2
   PubMed Web of Science ®Google Scholar
• Clark JA, Zimmerman HJ, Tanner LA Labetalol hepatotoxicity. Ann Intern Med. 1990; 113(3):210–213. 10.7326/0003-4819-113-3-210
   PubMed Web of Science ®Google Scholar
• Whiting RL, Dow RJ, Graham DJ, et al. An overview of the pharmacology and pharmacokinetics of nicardipine. Angiology. 1990;41(11 Pt 2):987–91.
   PubMed Web of Science ®Google Scholar
• Ye F, Lu Q, Kong B, et al. Clinical efficacy and safety of two concentrations of intravenous nicardipine hydrochloride for nicardipine-related phlebitis in patients with preeclampsia. Can J Physiol Pharmacol. 2022;100(4):291–4. doi: 10.1139/cjpp-2021-0387
   PubMed Web of Science ®Google Scholar
• Park I, Jeong MH, Park CJ, et al. Clinical features and management of “phlebitis-like abnormal reaction” after cyanoacrylate closure for the treatment of incompetent saphenous veins. Ann Vasc Surg. 2019;55:239–245. doi: 10.1016/j.avsg.2018.07.040
   PubMed Web of Science ®Google Scholar
• Igarashi A, Okuno T, Shimizu T, et al. Mechanical stimulation is a risk factor for phlebitis associated with peripherally inserted central venous catheter in neonates. Pediatr Int. 2021;63(5):561–4. doi: 10.1111/ped.14476
   PubMed Web of Science ®Google Scholar
• Murphy K, Murphy J, Fischer-Cartlidge E Reducing the Incidence of amiodarone-related phlebitis through utilization of evidence-based practice. Worldviews Evid Based Nurs. 2020; 17(5):385–392. 10.1111/wvn.12470
   PubMed Web of Science ®Google Scholar
• Mohammad NS, Nazli R, Zafar H, et al. Effects of lipid based multiple micronutrients supplement on the birth outcome of underweight pre-eclamptic women: a randomized clinical trial. Pak J Med Sci. 2022; 38(1):219–226. 10.12669/pjms.38.1.4396
   PubMed Web of Science ®Google Scholar
• Sher N, Mubaraki MA, Zafar H, et al. Effect of lipid-based multiple micronutrients supplementation in underweight primigravida pre-eclamptic women on maternal and pregnancy outcomes: randomized clinical trial. Medicina (Kaunas). 2022;58(12):1772. doi: 10.3390/medicina58121772
   PubMed Web of Science ®Google Scholar
• Yebyo HG, Aschmann HE, Kaufmann M, et al. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28. doi: 10.1016/j.ahj.2018.12.007
   PubMed Web of Science ®Google Scholar
• Tong S, Kaitu’u-Lino TJ, Hastie R, et al. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol. 2022; 226(2s):S1157–S1170. 10.1016/j.ajog.2020.09.014
   PubMedGoogle Scholar
• Brownfoot FC, Tong S, Hannan NJ, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66(3):687–97. discussion 445. doi: 10.1161/HYPERTENSIONAHA.115.05445
   PubMed Web of Science ®Google Scholar
• Onda K, Tong S, Beard S, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017;69(3):457–68. doi: 10.1161/HYPERTENSIONAHA.116.08408
   PubMed Web of Science ®Google Scholar
• Saleh L, Samantar R, Garrelds IM, et al. Low soluble fms-like tyrosine kinase-1, endoglin, and endothelin-1 levels in women with confirmed or suspected preeclampsia using proton pump inhibitors. Hypertension. 2017;70(3):594–600. doi: 10.1161/HYPERTENSIONAHA.117.09741
   PubMed Web of Science ®Google Scholar